ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1845

Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases

Taher Fatakdawala1, Michael Skawinski1, Jonathan Ferriera2, Tara Stauffer1 and Thomas Lavoie1, 1Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, 2Quality Control, PBL Assay Science, Piscataway, NJ

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biomarkers, cytokines, interferons and rheumatoid arthritis (RA), SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds tightly to IFN.  Soluble forms of IFNAR2 can be produced by proteolytic cleavage or production of an alternatively spliced transcript.  Soluble IFNAR2 can be found in serum and urine however its role and regulation are poorly understood.  Studies have suggested that sIFNAR2 may be elevated in multiple sclerosis (MS) patients, advanced cancer patients and hepatitis C infected patients.  We have examined the sIFNAR2 in healthy donors and a small set of autoimmune patients, to determine its suitability as a member of a biomarker panel for autoimmune diseases.

Methods: Healthy donor and autoimmune Sera and plasma were commercially sourced.  sIFNAR2 and IFN-Beta were determined by single analyte ELISA.  IP-10 and inflammatory cytokines were determined by multiplex ELISA.  IFN activity was determined by a reporter gene assay.  30 male and 30 female normal donor, 59 MS, 67 Systemic Lupus, 16 Rheumatoid Arthritis (RA), 11 Sjogren’s and 10 Scleroderma samples were examined.  Significance of observed differences was determined by 2-tail t-test using Welsh’s correction. 

Results:

The average sIFNAR2 levels are 2.6±0.7 ng/ml with no difference observed between male (n=30) and female healthy donors (n=30).  MS patients on IFN therapy (n=29) had significantly (p=0.0002) higher levels of sIFNAR2 than healthy donors.  Those on other therapies (n=24) were not different from the healthy population but were significantly different than the MS patients on IFN therapy (p=0.0001).  IFN-Beta mass was measurable in 86% of those patients treated with IFN.  IP-10 levels in these patients correlated with IFN dose (r=0.747) while sIFNAR2 did not.  sIFNAR2 levels showed no correlation with treatments such as vitamin-D, copaxone or natalizumab.  Systemic Lupus patients (n=67) had elevated sIFNAR2 (p=<0.0001).  Rheumatoid arthritis (n=16), Sjogren’s (n=11) and Scleroderma patients were not significantly different from normal.  

Conclusion:

Only subsets of autoimmune patients show elevated sIFNAR2 levels.  Although evidence of Type I IFN activation has been observed in RA, Sjogren’s and Scleroderma patients the intensity is thought to be less than that observed for MS patients on IFN-therapy  and Systemic Lupus.  These data are consistent with a model where long term IFN signaling above a certain threshold leads to elevated sIFNAR2.


Disclosure:

T. Fatakdawala,

PBL Assay Science,

3;

M. Skawinski,

PBL Assay Science,

3;

J. Ferriera,

PBL Assay Science,

3;

T. Stauffer,

PBL Assay Science,

3;

T. Lavoie,

PBL Assay Science,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/soluble-type-i-interferon-receptor-2-is-elevated-by-interferon-treatment-and-in-certain-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology